Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 15 May 2024 21:25:33 +0200Mon, 08 Jan 2024 11:58:00 +0100Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/icandra-previously-vildagliptin-metformin-hydrochloride-novartisHuman medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/icandra-previously-vildagliptin-metformin-hydrochloride-novartisMon, 08 Jan 2024 11:58:00 +0100Human medicineIcandra : EPAR - All Authorised presentationshttps://www.ema.europa.eu/system/files/documents/all-authorised-presentations/ema-other-h-1050-aa_en.pdfIcandra : EPAR - All Authorised presentationshttps://www.ema.europa.eu/system/files/documents/all-authorised-presentations/ema-other-h-1050-aa_en.pdfWed, 17 Jun 2020 11:00:00 +0200Human medicine